Clinical Trials Logo

Cystic Fibrosis Lung clinical trials

View clinical trials related to Cystic Fibrosis Lung.

Filter by:
  • None
  • Page 1

NCT ID: NCT06413459 Recruiting - Clinical trials for Non-Tuberculous Mycobacterial Pneumonia

Identification of New Biological Markers for the Progression of Mycobacterium Abscessus-induced Lung Disease in Cystic Fibrosis

BioMol-MA
Start date: April 8, 2021
Phase:
Study type: Observational

In this project we aim to identify new biological markers by characterizing the response inflammation associated with the development and progression of M. abscessus lung disease in patients suffering from cystic fibrosis with the aim of increasing current knowledge available on the development and progression of lung disease.

NCT ID: NCT06016088 Recruiting - Clinical trials for Pseudomonas Aeruginosa

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

Start date: April 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.

NCT ID: NCT05248230 Recruiting - Clinical trials for Cystic Fibrosis Lung

4D-710 in Adult Patients With Cystic Fibrosis

CF
Start date: March 29, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2 multicenter, open-label, single dose trial of 4D-710 investigational gene therapy in adults with CF who are ineligible for or unable to tolerate CFTR modulator therapy.

NCT ID: NCT03753828 Completed - Clinical trials for Cystic Fibrosis Lung

Estimated Impact of Fungal Colonization in Cystic Fibrosis From Secondary Exploitation of MucoFong Database.

MucoFong2
Start date: July 13, 2017
Phase:
Study type: Observational

The main objective of the project "MucoFong" (19021906 national french program n which Vaincre La Mucoviscidose participated: N82006/ 351) was to determine the fungi present the respiratory tract of CF patients responsible for either colonization or authentic infectious diseases. The Mucofong data allowed the team to provide for the 1st time national French guidelines for the management of CF sputum mycological analysis (MucoMicrobes work group coordinated by Prof. Plésiat published in 2015 in the REMIC book). Nevertheless, the team has a comprehensive database that it still has to analyze beyond these initial results. The main goal today is to clarify the role of fungi in the lung function degradation of these patients by studying the overall risk and estimated impact of fungal colonization in our cohort.

NCT ID: NCT03309358 Terminated - Cystic Fibrosis Clinical Trials

A Study of the Safety and Tolerability of Inhaled SNSP113 in Healthy Subjects and Subjects With Stable Cystic Fibrosis

Start date: September 28, 2017
Phase: Phase 1
Study type: Interventional

Although Cystic Fibrosis is a complex genetic disease affecting many organs, lung disease is the primary cause of mortality. The objective of this study is to determine the safety and tolerability of SNSP113 in healthy subjects and subjects with stable cystic fibrosis.